These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 9035089)
1. The FDA: a dromedary tale. Nat Biotechnol; 1997 Jan; 15(1):1. PubMed ID: 9035089 [No Abstract] [Full Text] [Related]
2. The impact of FDA reform. Trunzo J Med Device Technol; 2003 Apr; 14(3):36-7. PubMed ID: 12789699 [TBL] [Abstract][Full Text] [Related]
3. Will FDA relinquish the "gold standard" for new drug approval? Redefining "substantial evidence" in the FDA Modernization Act of 1997. Kulynych J Food Drug Law J; 1999; 54(1):127-49. PubMed ID: 11758555 [No Abstract] [Full Text] [Related]
4. The big gap at the FDA. Stipp D Fortune; 2002 Jul; 146(2):113-4, 116. PubMed ID: 12141178 [No Abstract] [Full Text] [Related]
8. The application of the patent laws to the drug approval process. Coggio BD; Cerrito FD Food Drug Law J; 1997; 52(4):345-55. PubMed ID: 10346669 [No Abstract] [Full Text] [Related]
9. International Conference on Harmonisation; guidance on viral safety evaluation of biotechnology products derived from cell lines of human or animal origin; availability--FDA. Notice. Fed Regist; 1998 Sep; 63(185):51074-84. PubMed ID: 10185809 [TBL] [Abstract][Full Text] [Related]
10. Sandoz sues FDA over delay in first biogeneric approval. Fox JL Nat Biotechnol; 2005 Nov; 23(11):1327-8. PubMed ID: 16273046 [No Abstract] [Full Text] [Related]
11. Path to approval proves rocky for copycat biodrugs. Wadman M Nature; 2005 Nov; 438(7065):154-5. PubMed ID: 16281004 [No Abstract] [Full Text] [Related]
12. Vision and will: the future of the FDA. Epstein D Oncologist; 2009 Apr; 14(4):317-9. PubMed ID: 19365098 [No Abstract] [Full Text] [Related]
13. FDA drug approvals: no worse is simply not good enough. Nat Biotechnol; 1996 Apr; 14(4):403. PubMed ID: 9630904 [No Abstract] [Full Text] [Related]
14. Current regulatory and legal considerations for follow-on biologics. Kingham RF; Lietzan E Clin Pharmacol Ther; 2008 Nov; 84(5):633-5. PubMed ID: 18716615 [No Abstract] [Full Text] [Related]
15. Regulatory watch: FDA guidance on co-developing investigational drugs. Nat Rev Drug Discov; 2011 Feb; 10(2):86. PubMed ID: 21283094 [No Abstract] [Full Text] [Related]
16. Recent developments help the defense of drug companies in 10b-5 cases. Salpeter AN; Hutchins H Food Drug Law J; 1996; 51(3):345-53. PubMed ID: 11797711 [No Abstract] [Full Text] [Related]